Pasireotide LAR
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-functioning Pituitary Adenoma
Conditions
Non-functioning Pituitary Adenoma
Trial Timeline
Nov 26, 2012 → Sep 12, 2017
NCT ID
NCT01283542About Pasireotide LAR
Pasireotide LAR is a phase 2 stage product being developed by Novartis for Non-functioning Pituitary Adenoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01283542. Target conditions include Non-functioning Pituitary Adenoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02354508 | Phase 3 | Completed |
| NCT01283542 | Phase 2 | Completed |
| NCT01673646 | Phase 2 | Completed |
| NCT01364415 | Phase 1 | Completed |
| NCT00958841 | Phase 2 | Terminated |